Open Access
ARTICLE
Secondary hormonal manipulations in the management of advanced prostate cancer
1
Department of Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
2
Department of Hematology/Oncology, Marshfield Clinic-Wausau Center, Wausau, Wisconsin, USA
3
Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Address correspondence to Dr. Nabil K. Bissada,
Department of Urology, UAMS, 800 Marshall Street, Little
Rock, Arkansas 72202 USA
Canadian Journal of Urology 2005, 12(3), 2666-2676.
Abstract
Prostate cancer is a heterogeneous disease and clinical outcomes vary considerably after failure of primary androgen ablation. With the development of new therapeutics the management of patients with androgen independent prostate cancer has changed considerably over the last few years. Multiple secondary hormonal manipulations are available and may lead to prolonged periods of clinical response. These maneuvers include the use of oral antiandrogens, antiandrogen withdrawal, ketoconazole, aminoglutethimide, corticosteroids and use of estrogenic compounds. This article reviews the clinical activity of these agents in management of patients with advanced prostate cancer.Keywords
Cite This Article

This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.